Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Revance Therapeutics (RVNC) Tops Q3 EPS by 2c
November 4, 2019 4:38 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.96), $0.02 better than the analyst estimate of ($0.98).
Revance is entering a pivotal period, given the large number of value-inflection points we have created for the company, beginning in just a few weeks with the anticipated submission of our first BLA for DAXI with the FDA, said Mark J. Foley, President and Chief... More
